PHVS
Pharvaris N.V.
NASDAQ · NLHealthcareBiotechnology
$33.55-3.98%
Price as of Jul 20, 2026
PHVS financials
Pharvaris N.V. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $169.8M | $145.7M | $96.9M | $86.7M |
| Operating income | -$169.8M | -$145.7M | -$96.9M | -$86.7M |
| Net income | -$175.7M | -$134.2M | -$100.9M | -$76.3M |
| EBITDA | -$173.3M | -$145.6M | -$99.6M | -$86.6M |
| Basic EPS | $-2.97 | $-2.48 | $-2.63 | $-2.27 |
| Diluted EPS | $-2.97 | $-2.48 | $-2.63 | $-2.27 |
| Balance sheet | ||||
| Cash & equivalents | $291.7M | $280.7M | $391.2M | $161.8M |
| Total assets | $301.5M | $291.4M | $398.7M | $167.7M |
| Total liabilities | $30.2M | $23.6M | $14.6M | $18.5M |
| Stockholders’ equity | $271.3M | $267.8M | $384.0M | $149.3M |
| Total debt | $776.8K | $861.5K | $238.9K | $436.8K |
| Net debt | -$290.9M | -$279.9M | -$391.0M | -$161.4M |
| Cash flow | ||||
| Operating cash flow | -$137.1M | -$120.1M | -$93.0M | -$67.2M |
| Capital expenditure | -$164.6K | -$538.1K | -$90.0K | -$124.3K |
| Free cash flow | -$137.2M | -$120.7M | -$93.1M | -$67.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |